Detail What is new in the 2018 Chinese hypertension guideline andthe implication for the management of hypertension in Asia? (article of Journal of Clinical Hypertension Mar 2020 Vol.22 Iss.3 p.363-368) Bibliografi Author: Wang, Ji-Guang ; Yook-Chin Chia ; Chen-Huan Chen ; Park, Sungha ; Hoshide, Satoshi ; Tomitani, Naoko ; Kabutoya, Tomoyuki ; Shin, Jinho ; Turana, Yuda ; Soenarta, Arieska Ann ; Jam Chin Tay ; Buranakitjaroen, Peera ; Nailes, Jennifer ; Huynh Van Minh ; Siddique, Saulat ; Sison, Jorge ; Sogunuru, Guru Prasad ; Sukonthasarn, Apichard ; Boon Wee Teo ; Verma, Narsingh ; Yu-qing Zhang ; Tzung-Dau Wang ; Kario, Kazuomi Topik: China; guideline; hypertension; management; JABFUNG-FKIK-YDT-2021-22 Bahasa: (EN )     Penerbit: Wiley Periodicals, Inc     Tahun Terbit: 2020     Jenis: Article - diterbitkan di jurnal ilmiah internasional Fulltext: B22 Jurnal Internasional Bereputasi dan Berfaktor dampak.pdf (338.85KB; 2 download) [Informasi yang berkaitan dengan koleksi ini di internet] Abstract The new Chinese hypertension guideline comprehensively covers almost all major aspects in the management of hypertension. In this new guideline, hypertension remains defined as a systolic/diastolic blood pressure of at least 140/90 mm Hg. For risk assessment, a qualitative approach is used similarly as in previous Chinese guidelines according to the blood pressure level and the presence or absence of other risk factors, target organ damage, cardiovascular complications, and comorbid diseases. The therapeutic target is 140/90 mm Hg in general, and if tolerated, especially in high-risk patients, can be more stringent, that is, 130/80 mm Hg. However, a less stringent target, that is, 150/90 mm Hg, is used in the younger (65-79 years, if tolerated, 140/90 mm Hg) and older elderly (=80 years). Five classes of antihypertensive drugs, including ß-blockers, can be used either in initial monotherapy or combination. The guideline also provided information on the management of hypertension in several special groups of patients and in the presence of secondary causes of hypertension. To implement the guideline recommendations, several nationwide hypertension control initiatives are being undertaken with new technology. The new technological platforms hopefully will help improve the management of hypertension and generate scientific evidence for future hypertension guidelines, including a possible Asian hypertension guideline in the near future. Opini Anda Klik untuk menuliskan opini Anda tentang koleksi ini! Lihat Sejarah Pengadaan  Konversi Metadata   Kembali

Copyright © 2006, 2007 Unika Atma Jaya, all rights reserved